Search

Displaying results 3241 - 3250 of 8171 in total
  1. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.

  2. Drug

    Elafibranor

    go.drugbank.com/drugs/DB05187
    ApprovedInvestigational

    Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist that works to inhibit bile acid synthesis. On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary b...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  3. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    The combination is an effective and well-tolerated malaria treatment, providing high cure rates even in areas of multi-drug resistance. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    ILY101

    go.drugbank.com/drugs/DB05059
    Investigational

    ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on d...

  5. Drug

    Dexchlorpheniramine

    go.drugbank.com/drugs/DB13679
    Investigational

    It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  6. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. … Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 Inducers
  7. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system.

  8. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    MAXY-G34 is a pegylated variant of human granulocyte-colony stimulating factor (G-CSF). This variant contains multiple non-naturally occurring lysines that have been introduced into alpha helixes of wild type human G-CSF as PEGylation si...

  9. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).

  10. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757] … CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.